Financial Report

Statement of financial position of PolyPeptide Group AG

As at 31 December

Assets, kCHF

Note

2022

2021

 

 

 

 

Current assets

 

 

 

Cash and cash equivalents

1

10,061

117,468

Other receivables from related parties

 

313

430

Other receivables from group companies

 

14,359

3,770

Accrued income and prepaid expenses

 

799

949

Total current assets

 

25,532

122,617

 

 

 

 

Non-current assets

 

 

 

Receivables from related parties

 

625

Receivables from group companies

 

137,744

66,027

Financial assets

3

2,463

2,736

Investments

2

759,300

1,919,700

Tangible assets

 

779

89

Total non-current assets

 

900,286

1,989,177

 

 

 

 

Total assets

 

925,818

2,111,794

Statement of financial position of PolyPeptide Group AG (continued)

As at 31 December

Liabilities, kCHF

Note

2022

2021

 

 

 

 

Current liabilities

 

 

 

Other liabilities due to third parties

 

644

580

Other liabilities due to related parties

 

14

8

Accrued expenses and deferred income

 

80

205

Total short-term liabilities

 

738

793

 

 

 

 

Non-current liabilities

 

 

 

Liabilities due to group companies

 

2,284

1,910

Total long-term liabilities

 

2,284

1,910

 

 

 

 

Shareholders' equity

 

 

 

Share capital

4

331

331

Statutory capital reserves

 

 

 

Reserves from capital contribution

5

2,104,803

2,114,719

Other capital reserves

 

4,949

4,949

Accumulated losses

 

 

 

Net loss brought forward

 

-9,604

Net loss for the year/period

 

-1,163,631

-9,604

Treasury shares

6

-14,052

-1,304

Total shareholders' equity

 

922,796

2,109,091

 

 

 

 

Total liabilities and shareholders' equity

 

925,818

2,111,794

This website uses cookies to ensure you get the best experience on our website.Privacy statement